Abstract:Background. While observation studies have shown a positive correlation between inflammatory bowel disease (IBD) and the risk of nonmalignant digestive system diseases, a definitive causal relationship has not yet been clearly established. Methods. Mendelian randomization (MR) was employed to investigate the potential causal association between genetic susceptibility to IBD and nonmalignant gastrointestinal diseases. Genetic variants were extracted as instrumental variables (IVs) from a genome-wide association study (GWAS) meta-analysis, which included 12,194 cases of Crohn's disease (CD) and 28,072 control cases of European ancestry. The GWAS for ulcerative colitis (UC) included 12,366 UC and 33,609 control cases of European ancestry. All IVs reached genome-wide significance (GWAS p value <5 × 10−8). Summary-level data for acute pancreatitis (AP), irritable bowel syndrome (IBS), gastroesophageal reflux disease, cholelithiasis, and CeD (celiac disease) were obtained from the GWAS meta-analysis and the FinnGen dataset. Summary-level data on relevant inflammatory factors were provided by the International Genetic Consortium. Univariate MR analysis was conducted using inverse variance weighting as the primary method for estimating causal effects. Multivariate MR analyses were also performed to detect possible mediators. Results. Genetic susceptibility to UC was associated with an increased risk of AP (OR = 1.08; 95% CI = 1.03–1.13; p=0.002 ) and IBS odds ratio (OR] = 1.07; 95% confidence interval (CI] = 1.03–1.11; ( p<0.001 ). In terms of potential mediators, interleukin 6 (IL-6) had a driving effect on the association between UC and AP. There was no apparent evidence of increased risk with CD. Meanwhile, genetic susceptibility to CD increases the risk of CeD (OR = 1.14; 95% CI = 1.03–1.25; p=0.01 ). Conclusions. The evidence suggests that UC is associated with an elevated risk of AP and IBS, and IL-6 may be responsible in AP. CD is associated with an increased risk of developing CeD. Implementing a proactive monitoring program for assessing the risk of gastrointestinal diseases in UC patients, particularly those with elevated IL-6 levels, may be of interest. In addition, the presence of AP and IBS may indicate the presence of UC. Preventing CeD is an essential consideration in the therapeutic management of patients with CD.

Mendelian randomization reveals predictive, preventive, and personalized insights into inflammatory bowel disease: the role of gut microbiome and circulating inflammatory proteins

Inflammatory proteins may mediate the causal relationship between gut microbiota and inflammatory bowel disease: A mediation and multivariable Mendelian randomization study

Causality Between Gut Microbiota and Inflammatory Bowel Disease: A Bidirectional Mendelian Randomization Study

Intestinal flora and inflammatory bowel disease: Causal relationships and predictive models

The Role of Inflammatory Biomarkers in Mediating the Effect of Inflammatory Bowel Disease on nonmalignant Digestive System Diseases: A Multivariable Mendelian Randomized Study

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Evaluating the causal effect of circulating proteome on the risk of inflammatory bowel disease-related traits using Mendelian randomization

Associations of inflammatory cytokines with inflammatory bowel disease: a Mendelian randomization study

Assessment of Causal Direction Between Gut Microbiota and Inflammatory Bowel Disease: A Mendelian Randomization Analysis

Platelet indices and inflammatory bowel disease: a Mendelian randomization study

Exploring inflammatory bowel disease therapy targets through druggability genes: a Mendelian randomization study

The influence of gut microbiota on circulating inflammatory cytokines and host: A Mendelian randomization study with meta-analysis

New Frontiers in Genetics, Gut Microbiota, and Immunity: A Rosetta Stone for the Pathogenesis of Inflammatory Bowel Disease

Exploring the casual association between gut microbiome, circulating inflammatory cytokines and chronic pancreatitis: A Mendelian randomization analysis

Exploring the intestinal ecosystem: from gut microbiota to associations with subtypes of inflammatory bowel disease

Genetically predict the association between 91 human blood cell perturbation phenotypes and IBD: A Mendelian randomization study

Causal relationship between circulating immune cells and inflammatory bowel disease: A Mendelian randomization analysis

GWAS-associated Bacteria and Their Metabolites Appear to Be Causally Related to the Development of Inflammatory Bowel Disease

Causality of genetically determined blood metabolites on inflammatory bowel disease: a two-sample Mendelian randomization study

The role of gut microbiome in inflammatory bowel disease diagnosis and prognosis

Integrating plasma proteomics with genome-wide association data to identify novel drug targets for inflammatory bowel disease